Format

Send to

Choose Destination
Vaccine. 2019 Feb 4;37(6):817-826. doi: 10.1016/j.vaccine.2018.12.049. Epub 2019 Jan 9.

Needle-free delivery of DNA: Targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza.

Author information

1
Biomedical Primate Research Centre, Rijswijk, the Netherlands.
2
K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, N-0027 Oslo, Norway. Electronic address: gunnveig.grodeland@medisin.uio.no.
3
K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, N-0027 Oslo, Norway.

Abstract

Conventional influenza vaccines are hampered by slow and limited production capabilities, whereas DNA vaccines can be rapidly produced for global coverage in the event of an emerging pandemic. However, a drawback of DNA vaccines is their generally low immunogenicity in non-human primates and humans. We have previously demonstrated that targeting of influenza hemagglutinin to human HLA class II molecules can increase antibody responses in larger animals such as ferrets and pigs. Here, we extend these observations by immunizing non-human primates (rhesus macaques) with a DNA vaccine encoding a bivalent fusion protein that targets influenza virus hemagglutinin (HA) to Mamu class II molecules. Such immunization induced neutralizing antibodies and antigen-specific T cells. The DNA was delivered by pain- and needle-free jet injections intradermally. No adverse effects were observed. Most importantly, the immunized rhesus macaques were protected against a challenge with influenza virus.

KEYWORDS:

APC-targeted antigen; Antigen presenting cell; DNA vaccine; Influenza; Non-human primates

PMID:
30638800
DOI:
10.1016/j.vaccine.2018.12.049
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Norwegian BIBSYS system
Loading ...
Support Center